Pulmonx Corporation's Upcoming Investor Engagements Revealed
Upcoming Investor Conferences for Pulmonx
Pulmonx Corporation (NASDAQ: LUNG) is a recognized leader in the realm of minimally invasive treatments for lung disease. As part of its commitment to transparency and investor engagement, the company has recently announced its participation in several notable investor conferences. These events provide a platform for Pulmonx to showcase its innovations and foster meaningful connections with industry stakeholders.
Details of the Wells Fargo Healthcare Conference
The first major appearance will be at the Wells Fargo Healthcare Conference. This event is designed to facilitate engaging discussions; Pulmonx's management will participate in a fireside chat segment and conduct one-on-one meetings. The conference is set for Thursday, September 4, at 1:30 PM PT / 4:30 PM ET. While specific location details are not disclosed, attendees can expect an insightful dialogue about Pulmonx’s strategic directions and growth prospects.
Participation in the Lake Street Best Ideas Growth Conference
Following this, Pulmonx will engage with attendees at the Lake Street Best Ideas Growth Conference on Thursday, September 11. This conference focuses on one-on-one meetings, enabling investors to ask direct questions and gain deeper insights into the company’s advancements and future strategies. It’s an exciting opportunity for investors to explore Pulmonx’s innovations and ask questions about their operations within the competitive healthcare landscape.
Webcast Availability
For those unable to attend the conferences in person, Pulmonx Corporation is committed to making the discussions accessible. A live and archived webcast of the fireside chat will be accessible via the "Investors" section on the Pulmonx website. This feature ensures that all interested stakeholders can stay informed about the company's latest developments and significant milestones.
About Pulmonx Corporation
Pulmonx Corporation, noted for its groundbreaking approaches towards treating chronic obstructive pulmonary disease (COPD), is particularly renowned for its flagship product, the Zephyr Endobronchial Valve. This innovative device has been instrumental for patients afflicted with severe emphysema who remain symptomatic despite standard medical care. The Zephyr Valve gained FDA pre-market approval, recognized as a “breakthrough device” due to its substantial therapeutic potential. Currently, it is available in over 25 countries and is included in global treatment guidelines, positioning it as a standard treatment option aimed at enhancing the quality of life for patients.
Investor Relations and Contact Information
Investors interested in delving deeper into Pulmonx’s offerings are encouraged to learn more about the company’s evolving strategies and product innovations. For inquiries or additional information regarding investor relations, they can reach out to Jeremy Feffer at LifeSci Advisors via email. Engaging with investor relations not only keeps stakeholders informed but also builds a strong relationship between the company and its investors.
Frequently Asked Questions
What is the purpose of Pulmonx's participation in investor conferences?
Pulmonx participates in investor conferences to engage with stakeholders, share insights about their strategies, and showcase their innovative products.
What key products does Pulmonx Corporation offer?
Pulmonx offers the Zephyr Endobronchial Valve, a leading treatment option for chronic obstructive pulmonary disease (COPD) and severe emphysema.
How can I access the conference webcasts?
The live and archived webcasts for Pulmonx's presentations will be available in the "Investors" section of their official website.
Who should I contact for more information about investor relations?
For more information, investors can contact Jeremy Feffer at LifeSci Advisors via email.
Where can I find more information about Pulmonx Corporation?
Additional information about Pulmonx Corporation and its product offerings can be found on their official website, www.Pulmonx.com.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.